Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CEACAM5 antibody
- Development stage
- Preclinical
- Lead developer
- PEP-Therapy
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
anti-CEACAM5 antibody is a preclinical-stage therapeutic candidate being developed by PEP-Therapy. It consists of a monoclonal antibody targeting Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) delivered intracellularly using PEP-Therapy's proprietary Cell-Penetrating Peptide (CPP) platform. This approach is designed to enable efficient intracellular delivery and endosomal escape of the antibody, allowing it to target intracellular CEACAM5 in colorectal cancer cells while minimizing off-target toxicity.
- Other names
- anti-CEACAM5 Abanti-CEACAM-5 Abanti-CEACAM 5 Ab
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on anti-CEACAM5 antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CEACAM5 antibody.